FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979707987> ?p ?o ?g. }

• W2979707987 abstract "Abstract Abstract 1485 Aim: Myeloablative chemotherapy followed by autologous PBSCT remains one treatment strategy in adult AML patients. Relapse has been shown higher for those who received the highest CD34+ PB doses. Although highly active against the leukemic bulk, intensive chemotherapy often spare the hardier leukemia stem cells (LSCs) responsible for relapse. Detection of MRD in harvest products may reflect inadequate in vivo purging at least in part responsible for relapses. Although recent data have challenged the CD34+CD38− phenotype of LSCs, this cell population remains generally considered enriched for LSCs. In this setting, MRD remaining during CR should be relatively enriched in CD34+CD38− leukemic cells and their persistence should correlate with disease recurrence. Methods: CD34+ cells were harvested after CR achievement in 123 AML patients [median age: 53 y (25–72)] treated by induction chemotherapy in our Institution between 10/1994 and 04/2003. Patients were included in different clinical trials planning autologous SC harvest in CR and autologous SCT in absence of donor or allogeneic SCT indication. Seventy-one of them received effectively autologous PBSCT. Harvests performed in 15 normal donors were used as controls. CD34/CD38 cell profile was analyzed in harvests in one single tube by multicolor flow cytometry using multiple MoAbs. The gating strategy was based on CD45low/SSC and CD34+CD45low cell populations from total FSC/SSC viable cells. Three populations of CD34+ were distinguished: CD34+CD38–; CD34+CD38low; and CD34+CD38+. Results: Patients from the entire cohort with higher percentage of CD34+ cells (cut-off level: 1%) in PBSC products were associated with shorter EFS [median: 5.6 months (3-y EFS: 13%) vs 13.6 (37%); p=0.0005] and OS [median: 10 months (3-y OS: 19%) vs 23.4 (47%); p=0.004]. This was also the case when analyzing only patients who received autologous SCT: [median EFS: 5 months (3-y EFS: 13%) vs 22.2 (48%); p=0.0006, and median OS: 9.1 months (3-y OS: 21%) vs 43.3 (57%); p=0.001]. Among CD34+ populations, only CD34+CD38– had a prognostic impact on EFS and OS. At a cut-off level of 0.9%, median EFS was 8.2 months (3-y EFS: 29%) for those with higher percentage vs 91.9 (62%) for those with lower percentage and median OS was 14.2 months (3-y OS: 36%) vs 95.4 (69%) respectively for the entire cohort. These results were confirmed in patients undergoing autologous SCT: median EFS was 7.3 months (3-y EFS: 31%) vs 91.1 (70%) (p= 0.05), and median OS was 14.4 months (3-y OS: 39%) vs 94.6 (80%). CD34+CD38low and CD34+CD38+ populations did not show any prognostic impact. Harvests from AML patients were divided into 3 groups: Group A: 51 patients with CR duration <1 y; Group B: 22 patients with CR duration >1 y; and Group C: 50 patients without relapse. Harvests from 15 normal donors (Group D) were used as controls. Significant differences were only observed when comparing Group A and Group D for total CD34+ cells (mean ± SEM 2.5 ± 0.5 vs 1.2 ± 0.3; p < 0.05) and CD34+CD38– (4.5 ± 0.7 vs 2.3 ± 0.5; p < 0.05). To confirm the prognostic value of CD34+CD38–, 19 patients (Group 1) with evidence of leukemic contamination in harvests (abnormal cytogenetics at presentation found in aphereses) were compared with 22 patients (Group 2) without evidence of contamination (abnormal cytogenetics at presentation not found in aphereses). Median EFS was 10.1 months (3-year EFS: 45%) in Group 2 vs 6.3 (13%) in Group 1 (p=0.01), and median OS was 36.6 months (3-year OS: 55%) vs 10.8 (23%), respectively (p=0.03). Harvests from 15 normal donors (Group 3) served as controls. Significant differences were noted in harvest products regarding CD34+CD38– between Group 1 and Group 3 (mean ± SEM 6.0 ± 1.5 vs 2.3 ± 0.5; p = 0.04) and Group 1 and Group 2 (6.0 ± 1.5 vs 2.4 ± 0.5; p = 0.03), while there were no differences between Group 2 and controls. There were no significant differences between groups regarding CD34+CD38low and CD34+CD38+. We also measured MFI of CD13, CD33, CD123, CD117 in CD34+ subpopulations. Phenotypes were compared among the different groups. Conclusions: Higher proportions of CD34+CD38− in apheresis products appear to reflect inadequate in vivo purging and distinguish samples as enriched in ‘leukemic cells’ from those with lower CD34+CD38− as largely constituted of ‘normal cells’. This could serve as detection of MRD and help to identify samples associated with high-risk of relapse after autologous SCT. Disclosures: No relevant conflicts of interest to declare." @default.
• W2979707987 created "2019-10-18" @default.
• W2979707987 creator A5004470581 @default.
• W2979707987 creator A5006793451 @default.
• W2979707987 creator A5014257321 @default.
• W2979707987 creator A5024404992 @default.
• W2979707987 creator A5028508696 @default.
• W2979707987 creator A5042899914 @default.
• W2979707987 creator A5072027146 @default.
• W2979707987 creator A5072412716 @default.
• W2979707987 creator A5078817313 @default.
• W2979707987 date "2012-11-16" @default.
• W2979707987 modified "2023-10-01" @default.
• W2979707987 title "Higher Percentage of CD34+CD38− Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predict Unsustained Complete Remission in AML" @default.
• W2979707987 doi "https://doi.org/10.1182/blood.v120.21.1485.1485" @default.
• W2979707987 hasPublicationYear "2012" @default.
• W2979707987 type Work @default.
• W2979707987 sameAs 2979707987 @default.
• W2979707987 citedByCount "0" @default.
• W2979707987 crossrefType "journal-article" @default.
• W2979707987 hasAuthorship W2979707987A5004470581 @default.
• W2979707987 hasAuthorship W2979707987A5006793451 @default.
• W2979707987 hasAuthorship W2979707987A5014257321 @default.
• W2979707987 hasAuthorship W2979707987A5024404992 @default.
• W2979707987 hasAuthorship W2979707987A5028508696 @default.
• W2979707987 hasAuthorship W2979707987A5042899914 @default.
• W2979707987 hasAuthorship W2979707987A5072027146 @default.
• W2979707987 hasAuthorship W2979707987A5072412716 @default.
• W2979707987 hasAuthorship W2979707987A5078817313 @default.
• W2979707987 hasConcept C10205521 @default.
• W2979707987 hasConcept C126322002 @default.
• W2979707987 hasConcept C141071460 @default.
• W2979707987 hasConcept C143998085 @default.
• W2979707987 hasConcept C159912055 @default.
• W2979707987 hasConcept C203014093 @default.
• W2979707987 hasConcept C2776694085 @default.
• W2979707987 hasConcept C2777371436 @default.
• W2979707987 hasConcept C2778461978 @default.
• W2979707987 hasConcept C28328180 @default.
• W2979707987 hasConcept C2908647359 @default.
• W2979707987 hasConcept C54355233 @default.
• W2979707987 hasConcept C71924100 @default.
• W2979707987 hasConcept C86803240 @default.
• W2979707987 hasConcept C90924648 @default.
• W2979707987 hasConcept C99454951 @default.
• W2979707987 hasConceptScore W2979707987C10205521 @default.
• W2979707987 hasConceptScore W2979707987C126322002 @default.
• W2979707987 hasConceptScore W2979707987C141071460 @default.
• W2979707987 hasConceptScore W2979707987C143998085 @default.
• W2979707987 hasConceptScore W2979707987C159912055 @default.
• W2979707987 hasConceptScore W2979707987C203014093 @default.
• W2979707987 hasConceptScore W2979707987C2776694085 @default.
• W2979707987 hasConceptScore W2979707987C2777371436 @default.
• W2979707987 hasConceptScore W2979707987C2778461978 @default.
• W2979707987 hasConceptScore W2979707987C28328180 @default.
• W2979707987 hasConceptScore W2979707987C2908647359 @default.
• W2979707987 hasConceptScore W2979707987C54355233 @default.
• W2979707987 hasConceptScore W2979707987C71924100 @default.
• W2979707987 hasConceptScore W2979707987C86803240 @default.
• W2979707987 hasConceptScore W2979707987C90924648 @default.
• W2979707987 hasConceptScore W2979707987C99454951 @default.
• W2979707987 hasLocation W29797079871 @default.
• W2979707987 hasOpenAccess W2979707987 @default.
• W2979707987 hasPrimaryLocation W29797079871 @default.
• W2979707987 hasRelatedWork W1966977246 @default.
• W2979707987 hasRelatedWork W1994075039 @default.
• W2979707987 hasRelatedWork W2107322811 @default.
• W2979707987 hasRelatedWork W2134542365 @default.
• W2979707987 hasRelatedWork W2525129705 @default.
• W2979707987 hasRelatedWork W2541352213 @default.
• W2979707987 hasRelatedWork W2551899293 @default.
• W2979707987 hasRelatedWork W2553025272 @default.
• W2979707987 hasRelatedWork W2558025721 @default.
• W2979707987 hasRelatedWork W2567321909 @default.
• W2979707987 hasRelatedWork W2571567455 @default.
• W2979707987 hasRelatedWork W2573872323 @default.
• W2979707987 hasRelatedWork W2585387293 @default.
• W2979707987 hasRelatedWork W2585634706 @default.
• W2979707987 hasRelatedWork W2589911589 @default.
• W2979707987 hasRelatedWork W2598704428 @default.
• W2979707987 hasRelatedWork W2979655028 @default.
• W2979707987 hasRelatedWork W2979758495 @default.
• W2979707987 hasRelatedWork W2980032371 @default.
• W2979707987 hasRelatedWork W2980140721 @default.
• W2979707987 isParatext "false" @default.
• W2979707987 isRetracted "false" @default.
• W2979707987 magId "2979707987" @default.
• W2979707987 workType "article" @default.